Recipharm appoints new Business Director for Italy and new General Manager at Pessac, France
Recipharm is pleased to announce the appointment of a new business director for the Italian pharmaceutical market and a new General Manager at Pessac, France.
Franco Boselli joins the Business Management team as Business Director in Italy with the main task to sell Recipharm’s full service offering to Italian pharmaceutical companies. He reports to the Vice President of Business Management, Kenth Berg, and is based in Milan.
Prior to joining Recipharm, Mr Boselli worked in marketing and sales in different pharmaceutical companies in Italy. In 2009, he joined the B2B business as Business Development Manager in Mipharm, the Italian CMO, specialising in non-sterile products. In 2011, he joined Biologici Italia Laboratories, later part of the Corvette group acquired by Recipharm last year, as Business Development Director. In this role, he managed Corvette’s key customers and was responsible for the scouting of new business, including the out-licensing of dossiers of sterile injectables and the development of new dossiers for generic products as well as sales of contract manufacturing of lyophilised and sterile formulations. Mr Boselli holds a degree in Economics from L. Bocconi University in Milan.
Bernard Pluta joins Recipharm as General Manager for the operating company in Pessac, France and will report to the Executive Vice President of Development and Technology, Carl-Johan Spak. Mr Pluta has had a long career in the pharma industry, having held executive positions in Theramex and Teva. He currently runs his own CMO consultancy business. Mr Pluta’s primary task is to drive the performance at the company through the sales of new projects and operational excellence. He commenced his role on October 19th, replacing Stéphane Guisado who will continue in his role as General Manager in Recipharm Fontaine. Mr Pluta holds a master degree in Engineering from the French Grande Ecole of Arts & Métiers in Paris and an executive MBA from Ashridge Business School, UK.
Commenting on the appointments, Thomas Eldered, CEO of Recipharm said: “I am delighted that Mr Boselli and Mr Pluta have joined Recipharm. Both bring great skills and experience to our organization. Mr Boselli’s knowledge and expertise will be invaluable to the continuing growth and expansion of our Italian business across the whole Recipharm network. Mr Pluta’s industry expertise and solid business competence will play a key role in the task at hand to increase performance at Recipharm Pessac whilst maintaining the highest quality standards of service.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance